You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK)預期中期淨利9億元-10.5億元
格隆匯 07-16 19:14

格隆匯7月16日丨 康希諾生物-B(06185.HK)公吿,根據集團目前可獲得的資料及對集團截至2021年6月30日止六個月("報吿期")未經審核綜合管理帳目作出初步評估,預期集團於報吿期內錄得淨利潤較2020年同期增長至扭虧為盈。

集團預計報吿期將實現歸屬於公司所有者的淨利潤約人民幣9億元至人民幣10.5億元(2020年同期,歸屬於公司所有者的淨虧損約人民幣1.022億元)。報吿期歸屬於公司所有者扣除非經常性損益後的淨利潤預期約人民幣8.5億元至人民幣10億元(2020年同期,歸屬於公司所有者扣除非經常性損益後的淨虧損約人民幣1.16億元)。

此外,集團預期報吿期內錄得收入約人民幣20億元至人民幣22億元(2020年同期,香港財務報吿準則下收入為0)。

據董事會所知,報吿期錄得利潤較2020年同期增長至扭虧為盈主要由於重組新型冠狀病毒疫苗(5型腺病毒載體)(商品名稱:克威莎)在國內外的銷售增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account